Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2/3 study of VDPHL01 for the treatment of androgenetic alopecia (AGA), or pattern hair loss (PHL)

Next Previous
X
Search
Trial Profile

Phase 2/3 study of VDPHL01 for the treatment of androgenetic alopecia (AGA), or pattern hair loss (PHL)

Status: Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 16 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VDPHL (Primary)
  • Indications Alopecia; Female pattern baldness; Male pattern baldness
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 16 Dec 2024 New trial record
    • 11 Dec 2024 According to a Veradermics media release, The first patient has been dosed in the pivotal Phase 2/3 trial evaluating VDPHL01 in AGA/PHL. The trial will enroll approximately 480 patients across 44 sites in the United States.The company plans to report topline data from the Phase 2 studies of VDPHL01 in the first half of 2025.
    • 11 Dec 2024 According to a Veradermics media release, the company aannounced the closing of a $75 million Series B financing. Proceeds from the financing will be used to fund the ongoing pivotal clinical development of Veradermics' lead candidate VDPHL01 for the treatment of androgenetic alopecia (AGA), or pattern hair loss (PHL).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top